Masitinib in Patients With Symptomatic Mild to Moderate COVID-19
Status:
Not yet recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
The objective of the study is to evaluate the anti-viral efficacy of 3 different dosages of
masitinib in patients with symptomatic mild to moderate COVID-19.